62 Results
Sort By:
Published on March 2, 2022
Hematopoietic stem cells (HSCs) have the capacity to both self-renew and differentiate into all mature blood cell types, making them promising treatments for a variety of diseases. However, the mechanisms involved in engraftment—when the cells start to grow and make healthy blood cells after being transplanted into a patient—are poorly…
Published on March 27, 2024
Researchers have developed a new atlas of rare hematopoietic stem and progenitor cells, those cells that trigger production of mature blood cells. Their studies showed that the atlas can aid in predicting which acute myeloid leukemia (AML) patients will respond to current standard therapy with venetoclax and azacytidine. The scientists…
Published on August 2, 2023
Just after 8:30 ET on Tuesday night a Commercial Resupply Services mission to the International Space Station (ISS) launched carrying 20 payloads of a diverse set of research projects to determine the benefits of working in microgravity. One of the projects, designed by Mayo Clinic and ClinImmune scientists in collaboration…
Published on April 13, 2022
Researchers based at the University of California, Los Angeles (UCLA) have created a detailed map of human blood cells and how they develop in an embryo, which could help improve treatments for blood-related disorders like leukemia and sickle-cell disease in the future. Hematopoietic stem cells are the early version of…
Published on September 8, 2021
New evidence suggests ganciclovir may alter stem cell transplant patients’ DNA, but that transplanted stem cells do not. That’s according to a study by Researchers in the Van Boxtel group at the Princess Máxima Center for pediatric oncology. The researchers analyzed the DNA of blood cells in nine patients who…
Published on November 5, 2018
What does not kill me makes me stronger. How often have we heard this dubious assertion? Well, sometimes it’s true, particularly at the cellular level, where cell subpopulations may possess genetic variants that confer survival advantages during adverse conditions—or after adverse conditions have ceased being so adverse. Something like a…
Published on August 17, 2018
Scientists in Copenhagen have developed a new tool for diagnosing and monitoring a wide variety of cancers, which uses a malaria protein known rVAR2 to grab hold of and remove circulating tumor cells (CTCs) from blood samples. The researchers, headed by Mette Ø. Agerbæk, Ph.D., and Ali Salanti, Ph.D., at…
Published on December 29, 2017
Using gene therapy, U.S. researchers have created chimeric antigen receptor (CAR)-engineered hematopoietic stem/progenitor cells (HSPCs) that have shown potential to treat HIV and other infections that can re-emerge after many years of suppression or dormancy. The CAR-engineered HSPCs were successfully engrafted in the bone marrow of pigtail macaques infected with…
Published on January 15, 2021
Research from the U.K.’s University of Birmingham explains how mutations in the RUNX1 gene can influence blood cell development and cause different types of cancer and other blood disorders. The RUNX1 gene encodes a protein that guides the way hematopoietic stem cells change into adult blood cells. Mutations in this…
Published on December 11, 2023
In a landmark moment for sickle cell disease treatment and CRISPR, two gene therapies were approved for the condition by the U.S. FDA. One of them,Vertex and CRISPR Therapeutics’ Casgevy (exagamglogene autotemcel [exa-cel]), is the first ever FDA approved CRISPR/Cas9 genome-edited cell therapy. Simultaneously, Bluebird Bio received the FDA OK…
Published on July 28, 2023
An RNA-based gene editing tool that alters red blood cells inside the body could provide a simpler and less toxic route to treating conditions such as sickle cell anemia and beta thalassemia, researchers report. The discovery, outlined in Science, offers an alternative to current gene therapy for these blood disorders,…
Published on October 25, 2022
By Anuj Kalsy Sponsored content brought to you by Repairing tissues and organs makes up a key goal of medicine, and many companies pursue this objective. By 2030, the regenerative-medicine market is projected to reach nearly $38 billion, based on an annual growth rate of more than 15% a…
Published on October 18, 2022
U.S. researchers at the University of California in Irvine have developed a mathematical model that they believe can help predict treatment response in patients with the white blood cell cancer chronic myeloid leukemia. The model identified patients most likely to respond well to treatment with tyrosine kinase inhibitors (TKIs) and…
Published on October 14, 2022
By Manrose Singh, Danny MacKenzie, Sanket Desai, Noelle Batista, and Dong Zhang Members of the Zhang lab at New York Institute of Technology Since the early 1990s, when telomerase was first cloned, targeting the telomere maintenance mechanism (TMM) to treat cancer has been considered to be…
Published on August 16, 2022
Jonathan ThonFounder, CEO, STRM.BIO A serial biotech entrepreneur, Jonathan Thon, is the founder and CEO of STRM.BIO, a pre-clinical, VC-backed biotechnology company that is leveraging extracellular vesicles (EVs) to deliver gene therapies. Prior to launching STRM.BIO, he founded and served as CEO / CSO of PlateletBio…